These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 848361)

  • 1. Spontaneous systemic lupus erythematosus and acelylator phenotype.
    Larsson R; Karlsson E; Molin L
    Acta Med Scand; 1977; 201(3):223-6. PubMed ID: 848361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.
    Morris RJ; Freed CR; Kohler PF
    Arthritis Rheum; 1979 Jul; 22(7):777-80. PubMed ID: 454504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
    Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
    Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus.
    Ishizaki T; Horai Y; Koya G; Matsuyama K; Iguchi S
    Arthritis Rheum; 1981 Oct; 24(10):1245-54. PubMed ID: 7306226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug acetylation and expression of lupus erythematosus.
    Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
    Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.
    Strandberg I; Boman G; Hassler L; Sjöqvist F
    Acta Med Scand; 1976; 200(5):367-71. PubMed ID: 983808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic acetylator phenotype and systemic lupus erythematosus.
    Johansson E; Mustakallio KK; Mattila MJ
    Acta Med Scand; 1981; 210(3):193-6. PubMed ID: 6974957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal distribution of acetylation phenotypes in systemic lupus erythematosus.
    Vansant J; Woosley RL; John JT; Sergent JS
    Arthritis Rheum; 1978 Mar; 21(2):192-5. PubMed ID: 637885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow acetylation phenotype in systemic lupus erythematosus.
    Fishbein E; Alarcón-Segovia D
    Arthritis Rheum; 1979 Jan; 22(1):95-7. PubMed ID: 758923
    [No Abstract]   [Full Text] [Related]  

  • 10. Acetylator phenotype in systemic lupus erythematosus.
    Foad B; Litwin A; Zimmer H; Hess EV
    Arthritis Rheum; 1977 Apr; 20(3):815-8. PubMed ID: 301027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylator phenotype in idiopathic systemic lupus erythematosus.
    Reidenberg MM; Levy M; Drayer DE; Zylber-Katz E; Robbins WC
    Arthritis Rheum; 1980 May; 23(5):569-73. PubMed ID: 7378086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases.
    Molin L; Larsson R; Karlsson E
    Acta Med Scand; 1977; 201(3):217-22. PubMed ID: 848360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation].
    Miscoria G; Leneveu A; Walle C; Roux A
    Ann Biol Clin (Paris); 1988; 46(9):734-40. PubMed ID: 3223632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.
    Lawson DH; Henry DA; Lowe J; Reavey P; Rennie JA; Solomon A
    Ann Rheum Dis; 1979 Apr; 38(2):171-3. PubMed ID: 443884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus.
    Reidenberg MM; Drayer DE; Lorenzo B; Strom BL; West SL; Snyder ES; Freundlich B; Stolley PD
    Arthritis Rheum; 1993 Jul; 36(7):971-3. PubMed ID: 8318043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between slow acetylator status and spontaneous lupus erythematosus.
    Kumana CR; Chan MM; Wong KL; Wong RW; Kou M; Lauder IJ
    Clin Pharmacol Ther; 1990 Aug; 48(2):208-13. PubMed ID: 2379389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.